FDA plans to roll out a suite of new policies in early 2018 that FDA Commissioner Scott Gottlieb told stakeholders Tuesday (Dec. 5) will help make the biologics and biosimilars space more sustainable and a viable area of competition. Gottlieb also discussed other ways FDA could reshape regulatory policies, chiefly by taking a more general approach to user fees to focus more on innovation and drug development, and ensuring user fee resources are more equally distributed throughout the agency. During...